Go to deals
Healthcare

Alcidion has completed a fundraising

Alcidion Group Ltd. (ASX:ALC) has raised funds to acquire Silverlink PCS Software Limited.

Alcidion is transforming healthcare with smart, intuitive technology solutions that provide real-time clinical decision support. The group integrates with EMR providers and assists doctors and nurses, covering functions such as streamlining patient journeys, smart analytics to help with clinical decisions, improving patient safety and productivity amongst clinical staff through messaging applications, and data capture and interpretation.

Oaklins’ team in Australia acted as joint underwriter, joint lead manager and joint bookrunner, alongside Canaccord Genuity (Australia) Ltd. The team has supported Alcidion in raising over US$70 million across three transactions, along with assisting shareholders to realize value via on-market trading, over the past three years.

Talk to the deal team

Justin Lewis

Managing Director
Melbourne, Australia
Oaklins Henslow

Scott McInnes

Managing Director
Melbourne, Australia
Oaklins Henslow

Related deals

Backspin has completed a mandatory public tender offer for the shares of Spindox
Private Equity | TMT

Backspin has completed a mandatory public tender offer for the shares of Spindox

Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.

Learn more
Rare Patient Voice has been acquired by Konovo
Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more